FPT Software Opens New Office in Denmark, Targeting Nordic Region
16.9.2022 00:15:00 EEST | Business Wire | Press release
FPT Software, Vietnam’s leading IT solutions provider, recently announced the opening of its first office in the Scandinavian region and the 59th office internationally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220905005353/en/
From left to right, FPT Software Europe CEO, Mr. Le Hai; FPT Corporation Chairman, Dr. Truong Gia Binh; Denmark’s State Secretary for Trade and Global Sustainability, H.E. Ms. Lina Gandløse Hansen; Vietnamese Ambassador to Denmark, H.E. Mr. Luong Thanh Nghi; Vido Group Founder, Ms. Nguyen Tuyet Mai; Vido Group Denmark CEO, Mr. Jesper G. Jensen. (Photo by Vietnam News Agency)
Within the framework of the Vietnam - Denmark Business Forum, FPT Software and Vido Group, Vietnam’s leading travel services provider, had a joint ribbon-cutting ceremony, marking both companies’ first footprint in Denmark. The event was hosted by the Embassy of Vietnam in Denmark, FPT Software and Vido Group, and was attended by Denmark’s State Secretary for Trade and Global Sustainability, H.E. Ms. Lina Gandløse Hansen, Vietnamese Ambassador to Denmark, H.E. Mr. Luong Thanh Nghi, and executives from Vietnam and Denmark’s companies.
The new office extends FPT Software’s presence in Europe to seven countries and aims at exploring opportunities for sustainable and innovative business growth. It is located in Kongens Lyngby, a commercial area and home to major companies, including Microsoft, COWI A/S, Bang & Olufsen, among others.
“Denmark is one of Vietnam’s largest foreign investors. As Vietnam’s leading corporation, FPT believes that with this newly opened office, we could contribute to strengthening the relationship between the two countries and act as a bridge between both sides’ businesses," FPT Chairman, Dr. Truong Gia Binh said. “We are committed to accompanying Danish and other Nordic customers with our investments, digital technologies, and talents,” he pledged.
“I am very pleased to see FPT Software, a Vietnamese pioneering company in IT services, open its representative office in Denmark. This is the first time a big Vietnamese enterprise has set foot in the Danish market, one with very high standards. FPT Software's presence in Denmark, one of the world's leading countries in technology and digital transformation, has shown that Vietnamese businesses can fully reach out to the world,” Vietnamese Ambassador to Denmark Luong Thanh Nghi said.
“I believe that the presence of enterprises like FPT in Denmark or Carlsberg and LEGO in Vietnam will contribute to promoting, strengthening, and deepening the comprehensive partnership between Vietnam and Denmark. The Embassy of Vietnam in Denmark is committed to supporting and serving the interests of the people and businesses of the two countries,” Vietnamese Ambassador to Denmark Luong Thanh Nghi added.
The ceremony was followed by two panel discussions on how businesses and governments of Vietnam and Denmark can cooperate to promote digital transformation and green transition, as demonstrated by successful cases and experiences from top enterprises like LEGO, Covestro, and Schaeffler. As the Head of the Private Economic Development Research Board under the Government's Advisory Council on Administrative Procedure Reform, Dr. Truong Gia Binh also shared his insights on these matters.
Scandinavia has been at the forefront of digital transformation. Being the region’s success story, the Danish Government recently launched a new digitalization strategy in May 2022 with the vision to accelerate green transition, increase growth, talents, and exports with digital innovations. This provides foreign investors in such fields as AI, Fintech, Robotics, among others, with opportunities to expand in Scandinavia. With the new office in Denmark, FPT Software can extend its support to organizations in the region to address their demands on digital talent and emerging technologies.
The newly inaugurated office asserts FPT Software’s rapid growth and a strong commitment to expanding its European team. 2022 marks FPT Software’s 10th year of operation in Europe. After a decade, FPT Software Europe currently has 500 employees working across seven countries in the region and serves a clientele of nearly 100 organizations, including RWE, Schaeffler, Airbus, E.ON, and more. The company sets sights on becoming one of the Top 10 Digital Transformation services providers in Europe by 2025.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with more than USD 632.5 million in revenue and 25,500 employees in 28 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 1,000+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005353/en/
Contact information
Media
Mai Duong (Ms.)
FPT Software
PR Manager
Email: MCP.PR@fsoft.com.vn
Website: https://www.fpt-software.com/newsroom/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom